0
     

Report Added
Report already added
Cancer Antibody Drug Conjugates Market - Global Outlook and Forecast 2022-2028

Cancer Antibody Drug Conjugates Market - Global Outlook and Forecast 2022-2028

This report contains market size and forecasts of Cancer Antibody Drug Conjugates in global, including the following market information:

Global Cancer Antibody Drug Conjugates Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cancer Antibody Drug Conjugates Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Cancer Antibody Drug Conjugates companies in 2021 (%)
The global Cancer Antibody Drug Conjugates market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
First & Second Generation ADCs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Antibody Drug Conjugates manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Cancer Antibody Drug Conjugates Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Type, 2021 (%)
First & Second Generation ADCs
Third Generation ADCs
Global Cancer Antibody Drug Conjugates Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Cancer Antibody Drug Conjugates Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Antibody Drug Conjugates revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cancer Antibody Drug Conjugates revenues share in global market, 2021 (%)
Key companies Cancer Antibody Drug Conjugates sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Cancer Antibody Drug Conjugates sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Cancer Antibody Drug Conjugates Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Antibody Drug Conjugates Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Antibody Drug Conjugates Overall Market Size
2.1 Global Cancer Antibody Drug Conjugates Market Size: 2021 VS 2028
2.2 Global Cancer Antibody Drug Conjugates Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Cancer Antibody Drug Conjugates Sales: 2017-2028
3 Company Landscape
3.1 Top Cancer Antibody Drug Conjugates Players in Global Market
3.2 Top Global Cancer Antibody Drug Conjugates Companies Ranked by Revenue
3.3 Global Cancer Antibody Drug Conjugates Revenue by Companies
3.4 Global Cancer Antibody Drug Conjugates Sales by Companies
3.5 Global Cancer Antibody Drug Conjugates Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Cancer Antibody Drug Conjugates Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Cancer Antibody Drug Conjugates Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Players in Global Market
3.8.1 List of Global Tier 1 Cancer Antibody Drug Conjugates Companies
3.8.2 List of Global Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Cancer Antibody Drug Conjugates Market Size Markets, 2021 & 2028
4.1.2 First & Second Generation ADCs
4.1.3 Third Generation ADCs
4.2 By Type - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
4.2.1 By Type - Global Cancer Antibody Drug Conjugates Revenue, 2017-2022
4.2.2 By Type - Global Cancer Antibody Drug Conjugates Revenue, 2023-2028
4.2.3 By Type - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
4.3 By Type - Global Cancer Antibody Drug Conjugates Sales & Forecasts
4.3.1 By Type - Global Cancer Antibody Drug Conjugates Sales, 2017-2022
4.3.2 By Type - Global Cancer Antibody Drug Conjugates Sales, 2023-2028
4.3.3 By Type - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
4.4 By Type - Global Cancer Antibody Drug Conjugates Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Cancer Antibody Drug Conjugates Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
5.2.1 By Application - Global Cancer Antibody Drug Conjugates Revenue, 2017-2022
5.2.2 By Application - Global Cancer Antibody Drug Conjugates Revenue, 2023-2028
5.2.3 By Application - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
5.3 By Application - Global Cancer Antibody Drug Conjugates Sales & Forecasts
5.3.1 By Application - Global Cancer Antibody Drug Conjugates Sales, 2017-2022
5.3.2 By Application - Global Cancer Antibody Drug Conjugates Sales, 2023-2028
5.3.3 By Application - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
5.4 By Application - Global Cancer Antibody Drug Conjugates Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Cancer Antibody Drug Conjugates Market Size, 2021 & 2028
6.2 By Region - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
6.2.1 By Region - Global Cancer Antibody Drug Conjugates Revenue, 2017-2022
6.2.2 By Region - Global Cancer Antibody Drug Conjugates Revenue, 2023-2028
6.2.3 By Region - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
6.3 By Region - Global Cancer Antibody Drug Conjugates Sales & Forecasts
6.3.1 By Region - Global Cancer Antibody Drug Conjugates Sales, 2017-2022
6.3.2 By Region - Global Cancer Antibody Drug Conjugates Sales, 2023-2028
6.3.3 By Region - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.4.2 By Country - North America Cancer Antibody Drug Conjugates Sales, 2017-2028
6.4.3 US Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.4.4 Canada Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.4.5 Mexico Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.5.2 By Country - Europe Cancer Antibody Drug Conjugates Sales, 2017-2028
6.5.3 Germany Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.4 France Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.5 U.K. Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.6 Italy Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.7 Russia Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.8 Nordic Countries Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.9 Benelux Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.6.2 By Region - Asia Cancer Antibody Drug Conjugates Sales, 2017-2028
6.6.3 China Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.4 Japan Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.5 South Korea Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.6 Southeast Asia Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.7 India Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.7.2 By Country - South America Cancer Antibody Drug Conjugates Sales, 2017-2028
6.7.3 Brazil Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.7.4 Argentina Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, 2017-2028
6.8.3 Turkey Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8.4 Israel Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8.5 Saudi Arabia Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8.6 UAE Cancer Antibody Drug Conjugates Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Corporate Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Cancer Antibody Drug Conjugates Major Product Offerings
7.1.4 Novartis Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.1.5 Novartis Key News
7.2 Merck
7.2.1 Merck Corporate Summary
7.2.2 Merck Business Overview
7.2.3 Merck Cancer Antibody Drug Conjugates Major Product Offerings
7.2.4 Merck Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.2.5 Merck Key News
7.3 Roche
7.3.1 Roche Corporate Summary
7.3.2 Roche Business Overview
7.3.3 Roche Cancer Antibody Drug Conjugates Major Product Offerings
7.3.4 Roche Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.3.5 Roche Key News
7.4 AbbVie
7.4.1 AbbVie Corporate Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Cancer Antibody Drug Conjugates Major Product Offerings
7.4.4 AbbVie Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.4.5 AbbVie Key News
7.5 UCB
7.5.1 UCB Corporate Summary
7.5.2 UCB Business Overview
7.5.3 UCB Cancer Antibody Drug Conjugates Major Product Offerings
7.5.4 UCB Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.5.5 UCB Key News
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporate Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Major Product Offerings
7.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.6.5 Bristol-Myers Squibb Key News
7.7 Stem CentRx
7.7.1 Stem CentRx Corporate Summary
7.7.2 Stem CentRx Business Overview
7.7.3 Stem CentRx Cancer Antibody Drug Conjugates Major Product Offerings
7.7.4 Stem CentRx Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.7.5 Stem CentRx Key News
7.8 Biogen Idec
7.8.1 Biogen Idec Corporate Summary
7.8.2 Biogen Idec Business Overview
7.8.3 Biogen Idec Cancer Antibody Drug Conjugates Major Product Offerings
7.8.4 Biogen Idec Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.8.5 Biogen Idec Key News
7.9 Nordic Nanovector
7.9.1 Nordic Nanovector Corporate Summary
7.9.2 Nordic Nanovector Business Overview
7.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Major Product Offerings
7.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.9.5 Nordic Nanovector Key News
7.10 Millennium
7.10.1 Millennium Corporate Summary
7.10.2 Millennium Business Overview
7.10.3 Millennium Cancer Antibody Drug Conjugates Major Product Offerings
7.10.4 Millennium Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.10.5 Millennium Key News
7.11 Biotest AG
7.11.1 Biotest AG Corporate Summary
7.11.2 Biotest AG Cancer Antibody Drug Conjugates Business Overview
7.11.3 Biotest AG Cancer Antibody Drug Conjugates Major Product Offerings
7.11.4 Biotest AG Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.11.5 Biotest AG Key News
7.12 PDL BioPharma
7.12.1 PDL BioPharma Corporate Summary
7.12.2 PDL BioPharma Cancer Antibody Drug Conjugates Business Overview
7.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Major Product Offerings
7.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.12.5 PDL BioPharma Key News
7.13 Progenics Pharmaceuticals
7.13.1 Progenics Pharmaceuticals Corporate Summary
7.13.2 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Business Overview
7.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Major Product Offerings
7.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.13.5 Progenics Pharmaceuticals Key News
7.14 Seattle Genetics
7.14.1 Seattle Genetics Corporate Summary
7.14.2 Seattle Genetics Business Overview
7.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Major Product Offerings
7.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.14.5 Seattle Genetics Key News
7.15 Viventia Biotechnologies
7.15.1 Viventia Biotechnologies Corporate Summary
7.15.2 Viventia Biotechnologies Business Overview
7.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Major Product Offerings
7.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.15.5 Viventia Biotechnologies Key News
7.16 AbGenomics Corporation
7.16.1 AbGenomics Corporation Corporate Summary
7.16.2 AbGenomics Corporation Business Overview
7.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Major Product Offerings
7.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.16.5 AbGenomics Corporation Key News
7.17 Helix BioPharma
7.17.1 Helix BioPharma Corporate Summary
7.17.2 Helix BioPharma Business Overview
7.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Major Product Offerings
7.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.17.5 Helix BioPharma Key News
8 Global Cancer Antibody Drug Conjugates Production Capacity, Analysis
8.1 Global Cancer Antibody Drug Conjugates Production Capacity, 2017-2028
8.2 Cancer Antibody Drug Conjugates Production Capacity of Key Manufacturers in Global Market
8.3 Global Cancer Antibody Drug Conjugates Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cancer Antibody Drug Conjugates Supply Chain Analysis
10.1 Cancer Antibody Drug Conjugates Industry Value Chain
10.2 Cancer Antibody Drug Conjugates Upstream Market
10.3 Cancer Antibody Drug Conjugates Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cancer Antibody Drug Conjugates Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Cancer Antibody Drug Conjugates in Global Market
Table 2. Top Cancer Antibody Drug Conjugates Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Cancer Antibody Drug Conjugates Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Cancer Antibody Drug Conjugates Revenue Share by Companies, 2017-2022
Table 5. Global Cancer Antibody Drug Conjugates Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Cancer Antibody Drug Conjugates Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Cancer Antibody Drug Conjugates Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Cancer Antibody Drug Conjugates Product Type
Table 9. List of Global Tier 1 Cancer Antibody Drug Conjugates Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Cancer Antibody Drug Conjugates Sales (K Pcs), 2017-2022
Table 15. By Type - Global Cancer Antibody Drug Conjugates Sales (K Pcs), 2023-2028
Table 16. By Application – Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Cancer Antibody Drug Conjugates Sales (K Pcs), 2017-2022
Table 20. By Application - Global Cancer Antibody Drug Conjugates Sales (K Pcs), 2023-2028
Table 21. By Region – Global Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Cancer Antibody Drug Conjugates Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Cancer Antibody Drug Conjugates Sales (K Pcs), 2017-2022
Table 25. By Region - Global Cancer Antibody Drug Conjugates Sales (K Pcs), 2023-2028
Table 26. By Country - North America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Cancer Antibody Drug Conjugates Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Cancer Antibody Drug Conjugates Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Cancer Antibody Drug Conjugates Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Cancer Antibody Drug Conjugates Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Cancer Antibody Drug Conjugates Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Cancer Antibody Drug Conjugates Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Cancer Antibody Drug Conjugates Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Cancer Antibody Drug Conjugates Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, (K Pcs), 2023-2028
Table 46. Novartis Corporate Summary
Table 47. Novartis Cancer Antibody Drug Conjugates Product Offerings
Table 48. Novartis Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Merck Corporate Summary
Table 50. Merck Cancer Antibody Drug Conjugates Product Offerings
Table 51. Merck Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Roche Corporate Summary
Table 53. Roche Cancer Antibody Drug Conjugates Product Offerings
Table 54. Roche Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. AbbVie Corporate Summary
Table 56. AbbVie Cancer Antibody Drug Conjugates Product Offerings
Table 57. AbbVie Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. UCB Corporate Summary
Table 59. UCB Cancer Antibody Drug Conjugates Product Offerings
Table 60. UCB Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Bristol-Myers Squibb Corporate Summary
Table 62. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Offerings
Table 63. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Stem CentRx Corporate Summary
Table 65. Stem CentRx Cancer Antibody Drug Conjugates Product Offerings
Table 66. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Biogen Idec Corporate Summary
Table 68. Biogen Idec Cancer Antibody Drug Conjugates Product Offerings
Table 69. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Nordic Nanovector Corporate Summary
Table 71. Nordic Nanovector Cancer Antibody Drug Conjugates Product Offerings
Table 72. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Millennium Corporate Summary
Table 74. Millennium Cancer Antibody Drug Conjugates Product Offerings
Table 75. Millennium Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. Biotest AG Corporate Summary
Table 77. Biotest AG Cancer Antibody Drug Conjugates Product Offerings
Table 78. Biotest AG Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. PDL BioPharma Corporate Summary
Table 80. PDL BioPharma Cancer Antibody Drug Conjugates Product Offerings
Table 81. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Progenics Pharmaceuticals Corporate Summary
Table 83. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Offerings
Table 84. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Seattle Genetics Corporate Summary
Table 86. Seattle Genetics Cancer Antibody Drug Conjugates Product Offerings
Table 87. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Viventia Biotechnologies Corporate Summary
Table 89. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Offerings
Table 90. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. AbGenomics Corporation Corporate Summary
Table 92. AbGenomics Corporation Cancer Antibody Drug Conjugates Product Offerings
Table 93. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 94. Helix BioPharma Corporate Summary
Table 95. Helix BioPharma Cancer Antibody Drug Conjugates Product Offerings
Table 96. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 97. Cancer Antibody Drug Conjugates Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 98. Global Cancer Antibody Drug Conjugates Capacity Market Share of Key Manufacturers, 2020-2022
Table 99. Global Cancer Antibody Drug Conjugates Production by Region, 2017-2022 (K Pcs)
Table 100. Global Cancer Antibody Drug Conjugates Production by Region, 2023-2028 (K Pcs)
Table 101. Cancer Antibody Drug Conjugates Market Opportunities & Trends in Global Market
Table 102. Cancer Antibody Drug Conjugates Market Drivers in Global Market
Table 103. Cancer Antibody Drug Conjugates Market Restraints in Global Market
Table 104. Cancer Antibody Drug Conjugates Raw Materials
Table 105. Cancer Antibody Drug Conjugates Raw Materials Suppliers in Global Market
Table 106. Typical Cancer Antibody Drug Conjugates Downstream
Table 107. Cancer Antibody Drug Conjugates Downstream Clients in Global Market
Table 108. Cancer Antibody Drug Conjugates Distributors and Sales Agents in Global Market

List of Figures
Figure 1. Cancer Antibody Drug Conjugates Segment by Type
Figure 2. Cancer Antibody Drug Conjugates Segment by Application
Figure 3. Global Cancer Antibody Drug Conjugates Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Cancer Antibody Drug Conjugates Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Cancer Antibody Drug Conjugates Revenue, 2017-2028 (US$, Mn)
Figure 7. Cancer Antibody Drug Conjugates Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Cancer Antibody Drug Conjugates Revenue in 2021
Figure 9. By Type - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 10. By Type - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 11. By Type - Global Cancer Antibody Drug Conjugates Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 13. By Application - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 14. By Application - Global Cancer Antibody Drug Conjugates Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 16. By Region - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 17. By Country - North America Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 18. By Country - North America Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 19. US Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 24. Germany Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 25. France Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 33. China Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 37. India Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 39. By Country - South America Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 40. Brazil Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
Figure 44. Turkey Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Cancer Antibody Drug Conjugates Revenue, (US$, Mn), 2017-2028
Figure 48. Global Cancer Antibody Drug Conjugates Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Cancer Antibody Drug Conjugates by Region, 2021 VS 2028
Figure 50. Cancer Antibody Drug Conjugates Industry Value Chain
Figure 51. Marketing Channels

Report Title: Cancer Antibody Drug Conjugates Market - Global Outlook and Forecast 2022-2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments – Forecast to 2027

Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments – Forecast to 2027

Global Point of Care Testing (POCT) Market (By Diagnostics Segment, Mode, Platform, End Users, Region), Impact of COVID-19, Recent Developments, Company Profiles - Forecast to 2028

Global Point of Care Testing (POCT) Market (By Diagnostics Segment, Mode, Platform, End Users, Region), Impact of COVID-19, Recent Developments, Company Profiles - Forecast to 2028

Animal Wound Care Market by Product (Surgical (Sutures & Staplers, Glues), Advanced (Hydrocolloid, Hydrogel Dressings), Traditional (Tape, Dressings, Bandages), Animal Type (Cats, Dogs, Horse, Pigs), End User (Hospital, Clinics) - Global Forecast to 2027

Animal Wound Care Market by Product (Surgical (Sutures & Staplers, Glues), Advanced (Hydrocolloid, Hydrogel Dressings), Traditional (Tape, Dressings, Bandages), Animal Type (Cats, Dogs, Horse, Pigs), End User (Hospital, Clinics) - Global Forecast to 2027

Veterinary Ultrasound Market by Type (2D, 3D/4D, Doppler), Product (Portable Scanners), Technology (Contrast, Digital), Animal Type (Small, Large), Application (Gynecology, Cardiology, Orthopedics), End User (Clinics, Hospitals) - Global Forecast to 2027

Veterinary Ultrasound Market by Type (2D, 3D/4D, Doppler), Product (Portable Scanners), Technology (Contrast, Digital), Animal Type (Small, Large), Application (Gynecology, Cardiology, Orthopedics), End User (Clinics, Hospitals) - Global Forecast to 2027

Laboratory Animal Models, 3D Cultures and Organoids: Global Markets

Laboratory Animal Models, 3D Cultures and Organoids: Global Markets

Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027

Neuromodulation Market by Type (Internal (Deep Brain Stimulation, Vagus Nerve Stimulation), External (Transcranial Magnetic Stimulation)), Application (Parkinson's Disease, Depression, Urine incontinence, Epilepsy, Obesity) - Global Forecast to 2027